ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
Reduced-dose dexamethasone premedication for weekly paclitaxel: a retrospective cohort study of early hypersensitivity reactions and steroid-related toxicity.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTaxane-induced hypersensitivity reactions (HSRs) are highly prevalent, necessitating premedication with dexamethasone; however, prolonged or high-dose exposure to dexamethasone increases the risk of adverse effects. This study evaluated whether a reduced-dose dexamethasone regimen effectively prevents HSRs while minimizing steroid-related toxicity during weekly paclitaxel chemotherapy.
methodsThis retrospective cohort study utilized electronic health records to evaluate patients receiving weekly paclitaxel. We compared a low-dose (LD) dexamethasone regimen (10 mg at the first infusion, followed by 4 mg weekly) with a conventional high-dose (HD) regimen (10 mg weekly). The primary outcome was the incidence of HSRs during the second paclitaxel infusion, analyzed using non-inferiority testing with a predefined margin of 2%. Propensity score-based inverse probability of treatment weighting was employed to control confounding, with missing data addressed via multiple imputation. Secondary outcomes included the incidence of steroid-related adverse events (AEs) such as hyperglycemia, insomnia, and serious bacterial infections, evaluated using Cox proportional hazards models adjusted for relevant clinical factors.
resultsThe LD regimen was non-inferior to the HD regimen for preventing HSRs (weighted incidence, 0.72% vs. 1.18%; risk difference -0.46%; 95% CI -1.26% to 0.53%). The HD group had a significantly higher risk of hyperglycemia (adjusted HR [aHR] 1.54, 95% confidence interval [CI] 1.15 to 2.07). While insomnia (aHR 1.53, 95% CI 0.93 to 2.51) and serious bacterial infections (aHR 1.19, 95% CI 0.99 to 1.44) occurred more frequently in the HD group, these trends did not reach statistical significance.
conclusionA low-dose dexamethasone premedication regimen was non-inferior to the conventional regimen in preventing HSRs and was associated with a lower risk of corticosteroid-associated hyperglycemia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.